We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Atea Pharmaceuticals Inc | NASDAQ:AVIR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.13 | 3.39% | 3.96 | 3.84 | 4.99 | 3.96 | 3.795 | 3.89 | 164,714 | 05:00:07 |
From May 2021 to May 2024
By Chris Wack
Atea Pharmaceuticals Inc. said it has achieved a milestone associated with the development of AT-527, and expects to receive a related payment under its license agreement with Roche of $50 million.
Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of Covid-19.
AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea's purine nucleotide pro-drug platform, and it is in Phase 3 development for the treatment of Covid-19, Atea said.
Atea retains rights to commercialize AT-527 in the U.S., and Roche has the exclusive right to commercialize AT-527 outside the U.S.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 16, 2021 07:41 ET (11:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Atea Pharmaceuticals Chart |
1 Month Atea Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
